I agree Hoofa,
As an ex shareholder with a long memory, my take is the deal is nice validation of their underlying technology which was never in doubt, but it also reflects ResApps struggle to execute their commercial plan to date and create significant value.
For some context, ResApps has struggled at critical inflection points:
- SMARTCOUGH-C trial was a total failure
- MSF, Lockheed Martin, Sanofi and other deals never materialising
- Failed Coviu and Pheonix Health Integrations
- Sleepcheck App launch and bizarre pivot into medical hardware, cough counting
- Continuous Cap Raises
The BOD had to recommend the deal and clauses which are standard terms in a scheme of arrangement, why wouldn’t you endorse 11.5c.
It’s greater than the market price offered by shareholders at the time and offers a liquidity event.
ResApp has always been a R&D company.
Pfizer will know how to get FDA approval within 6 months and use their brand to commercialise the technology successfully and save lives, which is ultimately what ResApp is all about.
